Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $2.3 million.

  • Ensysce Biosciences' Total Liabilities fell 1783.41% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 1783.41%. This contributed to the annual value of $2.2 million for FY2024, which is 3399.64% down from last year.
  • Per Ensysce Biosciences' latest filing, its Total Liabilities stood at $2.3 million for Q3 2025, which was down 1783.41% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Total Liabilities registered a high of $24.6 million during Q4 2021, and its lowest value of $1.3 million during Q2 2024.
  • Its 5-year average for Total Liabilities is $6.6 million, with a median of $3.7 million in 2021.
  • In the last 5 years, Ensysce Biosciences' Total Liabilities skyrocketed by 25056.47% in 2021 and then plummeted by 8599.07% in 2023.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Total Liabilities stood at $24.6 million in 2021, then crashed by 59.66% to $9.9 million in 2022, then plummeted by 66.12% to $3.4 million in 2023, then tumbled by 34.0% to $2.2 million in 2024, then increased by 3.94% to $2.3 million in 2025.
  • Its Total Liabilities stands at $2.3 million for Q3 2025, versus $2.5 million for Q2 2025 and $1.9 million for Q1 2025.